AC
HAE icon

Aristides Capital’s Haemonetics HAE Stock Holding History

Aristides Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,724
Closed -$271K – 136
2020
Q1 		$271K Sell
2,724
-1,791
-40% -$194K 0.2% 78
2019
Q4 		$519K Buy
+4,515
New +$546K 0.4% 105

Other funds holding HAE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aristides Capital's HAE Position: Q2 2020 in Review

Aristides Capital sold out of Haemonetics (HAE) in Q2 2020, closing a stake of 2,724 shares — an estimated $271K sold.

Aristides Capital first reported a position in HAE in Q4 2019 and held it in 2 quarters. The position peaked at $519K in Q4 2019. 285 funds tracked by Wall St. Rank hold HAE as of Q2 2020.

  • Aristides Capital reported no remaining Haemonetics position as of Q2 2020 after selling out during the quarter.
  • Aristides Capital sold 2,724 Haemonetics shares in Q2 2020, an estimated $271K.
  • Aristides Capital first reported a position in Haemonetics in Q4 2019 and held it in 2 quarters.
  • Aristides Capital's Haemonetics position peaked at $519K in Q4 2019.
  • 285 funds tracked by Wall St. Rank held Haemonetics as of Q2 2020.

Based on Aristides Capital's 13F filing for Q2 2020, filed 14 Aug 2020.